I-Mab (NASDAQ:NBP) SVP Cong Claire Xu Sells 3,494 Shares of Stock

I-Mab (NASDAQ:NBP) SVP Cong Claire Xu sold 3,494 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $3.94, for a total value of $13,766.36. Following the completion of the transaction, the senior vice president owned 290,154 shares of the company’s stock, valued at approximately $1,143,206.76. The trade was a 1.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

I-Mab Stock Performance

NBP opened at $1.71 on Wednesday. The stock has a market cap of $197.76 million, a PE ratio of -4.75 and a beta of 1.47. The company has a 50 day moving average price of $2.27. I-Mab has a 52 week low of $1.28 and a 52 week high of $6.79.

I-Mab (NASDAQ:NBP) last announced its quarterly earnings data on Wednesday, April 8th. The company reported ($0.30) earnings per share (EPS) for the quarter. Sell-side analysts predict that I-Mab will post -0.56 EPS for the current fiscal year.

Analyst Ratings Changes

NBP has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of I-Mab in a research note on Wednesday, April 8th. Wall Street Zen cut I-Mab from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Weiss Ratings upgraded I-Mab from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $9.00.

Institutional Trading of I-Mab

A hedge fund recently bought a new stake in I-Mab stock. Taikang Asset Management Hong Kong Co Ltd bought a new position in I-Mab (NASDAQ:NBP) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 128,765 shares of the company’s stock, valued at approximately $512,000. Taikang Asset Management Hong Kong Co Ltd owned approximately 0.11% of I-Mab at the end of the most recent quarter. 38.38% of the stock is currently owned by institutional investors and hedge funds.

About I-Mab

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.